AIDDISON: Empowering Drug Discovery with AI/ML and CADD Tools in a Secure, Web-Based SaaS Platform.

Journal: Journal of chemical information and modeling
PMID:

Abstract

The widespread proliferation of artificial intelligence (AI) and machine learning (ML) methods has a profound effect on the drug discovery process. However, many scientists are reluctant to utilize these powerful tools due to the steep learning curve typically associated with them. AIDDISON offers a convenient, secure, web-based platform for drug discovery, addressing the reluctance of scientists to adopt AI and ML methods due to the steep learning curve. By seamlessly integrating generative models, ADMET property predictions, searches in vast chemical spaces, and molecular docking, AIDDISON provides a sophisticated platform for modern drug discovery. It enables less computer-savvy scientists to utilize these powerful tools in their daily activities, as demonstrated by an example of identifying a valuable set of molecules for lead optimization. With AIDDISON, the benefits of AI/ML in drug discovery are accessible to all.

Authors

  • Andrew Rusinko
    MilliporeSigma, 400 Summit Drive, Burlington, Massachusetts 01803, United States.
  • Mohammad Rezaei
    Sleep Disorders Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • Lukas Friedrich
    Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH), Vladimir-Prelog-Weg 4, CH-, 8093, Zurich, Switzerland.
  • Hans-Peter Buchstaller
    Merck Healthcare KGaA, Medicinal Chemistry and Drug Design, Darmstadt 64293, Germany.
  • Daniel Kuhn
    Merck Healthcare KGaA, Medicinal Chemistry and Drug Design, Darmstadt 64293, Germany.
  • Ashwini Ghogare
    MilliporeSigma, 400 Summit Drive, Burlington, Massachusetts 01803, United States.